Clinical Trials · NCT07783282
A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer
- Phase
- Phase 1
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Astellas Pharma Global Development, Inc.
- Enrollment
- 56
- Start date
- Aug 2026
- Locations
- See registry
- Primary endpoint
- Pharmacokinetics (PK) of Fezolinetant in plasma: Maximum Concentration (Cmax)